- Oral presentation
- Open Access
Can ultrasound contrast agents increase the treatment envelope?
© McDannold et al; licensee BioMed Central Ltd. 2015
- Published: 30 June 2015
- Nonhuman Primate
- Focal Region
- Acoustic Field
- Unresolved Issue
- Thermal Ablation
Currently, thermal ablation via transcranial MRI-guided focused ultrasound is restricted to centrally-located regions in the brain. This limitation is the result of skull heating when the focal region is steered to more peripheral regions in the brain, along with other factors such as limitations in beam steering in the currently-available clinical brain focused ultrasound systems. The treatment envelope could be expanded if the time averaged acoustic power needed for ablation could be reduced.
The introduction of ultrasound contrast agents – preformed microbubbles that are injected intravenously – can reduce the power needed to ablate tissue. These commercially-available microbubble agents respond strongly to an acoustic field, even at low intensities, and greatly magnify the resulting bioeffects.
This presentation will provide a summary of animal data obtained in small animals and in nonhuman primates at our institution and by others that tested contrast-enhanced ultrasound ablation. Overall, these studies have demonstrated that ablation can be achieved at time-averaged acoustic power levels at least an order of magnitude less than what is needed for thermal ablation.
The huge reduction in acoustic power that can be achieved with ablation combined with ultrasound contrast agents may enable a substantial increase in the “treatment envelope” for transcranial focused ultrasound systems. New methods are being developed to control the procedure and to ensure that unwanted tissue effects do not occur outside of the focal region. These developments, along with other unresolved issues with this mode of ablation will be topics for discussion.
Funding: Focused Ultrasound Foundation; NIH grants P01CA174645, P41EB015898
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.